Patterns of care in dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the tamoxifen exemestane adjuvant multinational (TEAM) trial

Annals of Oncology

Volumn 21, Issue 5, 2009, Pages 974-982

  van Nes, J G H ^a   Seynaeve, C ^b   Maartense, E ^c   Roumen, R M H ^d   de Jong, R S ^e   Beex, L V A M ^f   Meershoek Klein Kranenbarg, W M ^a   Putter, H ^c   Nortier, J W R ^a   van de Velde, C J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Reinier de Graaf Gasthuis ^*  (Netherlands)

^d MÁXIMA MEDICAL CENTER   (Netherlands)

^e MARTINI HOSPITAL   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Endocrine therapy; Guideline; Patterns of care

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY CANCER; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; NETHERLANDS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME;

AGED; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERNATIONAL AGENCIES; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PHYSICIAN'S PRACTICE PATTERNS; POSTMENOPAUSE; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 77953338835     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp419     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431-2442.
3. Boccardo F, Rubagotti A, Guglielmini P et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006; 17 (Suppl 7): vii10-vii14.
4. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559-570.
5. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
6. Ingle JN, Tu D, Pater JL et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008; 19: 877-882.
7. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462.
8. Koeberle D, Thurlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Res Treat 2007; 105 (Suppl 1): 55-66.
9. Schaapveld M, de Vries EG, Otter R et al. Guideline adherence for early breast cancer before and after introduction of the sentinel node biopsy. Br J Cancer 2005; 93: 520-528.
10. Sukel MP, van de Poll-Franse LV, Nieuwenhuijzen GA et al. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands. Eur J Cancer 2008; 44: 1846-1854.
11. Voogd AC, Repelaer van Driel OJ, Roumen RM et al. Changing attitudes towards breast-conserving treatment of early breast cancer in the south-eastern Netherlands: results of a survey among surgeons and a registry-based analysis of patterns of care. Eur J Surg Oncol 1997; 23: 134-138.
12. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
13. Markopoulos C. Aromatase inhibitors in the management of early breast cancer: the TEAM trial. Eur J Surg Oncol 2009; 35: 333.
14. st San Antonio Breast Cancer Symposium Abstr 81) 10-14 December 2008, San Antonio, TX.
15. Albain KS, Green SR, Lichter AS et al. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breastsparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol 1996; 14: 3009-3017.
16. White J, Morrow M, Moughan J et al. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer 2003; 97: 893-904.
17. Morrow M, White J, Moughan J et al. Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma. J Clin Oncol 2001; 19: 2254-2262.
18. Nattinger AB. Variation in the choice of breast-conserving surgery or mastectomy: patient or physician decision making? J Clin Oncol 2005; 23: 5429-5431.
19. Reitsamer R, Menzel C, Glueck S et al. Predictors of mastectomy in a certified breast center-the surgeon is an independent risk factor. Breast J 2008; 14: 324-329.
20. Dixon JM, Mak C. Predictors of mastectomy in a certified breast center-the surgeon is an independent risk factor. Breast J 2008; 14: 32-33.
21. Locker GY, Sainsbury JR, Cuzick J. Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy. Cancer 2004; 101: 735-740.
22. Vulto AJ, Lemmens VE, Louwman MW et al. The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in South Netherlands, 1995 to 2002. Cancer 2006; 106: 2734-2742.
23. Ballard-Barbash R, Potosky AL, Harlan LC et al. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst 1996; 88: 716-726.
24. Rutgers EJ, Meijnen P, Bonnefoi H. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res 2004; 6: 165-169.
25. Jassem J, Hall E, Bliss JM et al. Approaches to adjuvant chemotherapy in postmenopausal breast cancer patients in the Intergroup Exemestane Study. Breast Cancer Res Treat 2004; 27th San Antonio Breast Cancer Symposium (Abstr 1066). 8-11 December 2004, San Antonio, TX.
26. Albain KS, de la Garza SJ, Pienkowski T et al. Reducing the global breast cancer burden: the importance of patterns of care research. Clin Breast Cancer 2005; 6: 412-420.
27. Joslyn SA. Racial differences in treatment and survival from early-stage breast carcinoma. Cancer 2002; 95: 1759-1766.
28. Sainsbury R, Haward B, Rider L et al. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet 1995; 345: 1265-1270.
29. Hebert-Croteau N, Brisson J, Latreille J et al. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 2004; 22: 3685-3693.
30. Chang JH, Vines E, Bertsch H et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer 2001; 91: 1231-1237.
31. Petrisek AC, Laliberte LL, Allen SM, Mor V. The treatment decision-making process: age differences in a sample of women recently diagnosed with nonrecurrent, early-stage breast cancer. Gerontologist 1997; 37: 598-608.